ZOMDF (Zomedica) Cyclically Adjusted PB Ratio: (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Zomedica Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zomedica  (OTCPK:ZOMDF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Zomedica Cyclically Adjusted PB Ratio Related Terms


Zomedica Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Zomedica's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zomedica Cyclically Adjusted PB Ratio Chart

Zomedica Annual Data
Trend Feb16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.52 1.63 0.90 0.72

Zomedica Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.56 0.72 0.83 0.67

ZOMDF vs SERA, HYPR, OM: Cyclically Adjusted PB Ratio Comparison

For the Medical Devices subindustry, Zomedica's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zomedica Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zomedica's Cyclically Adjusted PB Ratio falls into.



Zomedica Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Zomedica's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Zomedica's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.109/333.9520*333.9520
=0.109

Current CPI (Jun. 2026) = 333.9520.

Zomedica Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.059 241.428 0.082
201612 0.046 241.432 0.064
201703 0.033 243.801 0.045
201706 0.048 244.955 0.065
201709 0.069 246.819 0.093
201712 0.049 246.524 0.066
201803 0.040 249.554 0.054
201806 0.050 251.989 0.066
201809 0.031 252.439 0.041
201812 0.037 251.233 0.049
201903 -0.017 254.202 -0.022
201906 -0.040 256.143 -0.052
201909 -0.064 256.759 -0.083
201912 -0.091 256.974 -0.118
202003 -0.078 258.115 -0.101
202006 0.049 257.797 0.063
202009 0.073 260.280 0.094
202012 0.080 260.474 0.103
202103 0.285 264.877 0.359
202106 0.282 271.696 0.347
202109 0.277 274.310 0.337
202112 0.276 278.802 0.331
202203 0.275 287.504 0.319
202206 0.272 296.311 0.307
202209 0.274 296.808 0.308
202212 0.273 296.797 0.307
202303 0.268 301.836 0.297
202306 0.265 305.109 0.290
202309 0.266 307.789 0.289
202312 0.245 306.746 0.267
202403 0.237 312.332 0.253
202406 0.213 314.175 0.226
202409 0.207 315.301 0.219
202412 0.200 315.605 0.212
202503 0.135 319.799 0.141
202506 0.128 322.561 0.133
202509 0.122 324.800 0.125
202512 0.118 324.054 0.122
202603 0.113 330.213 0.114
202606 0.109 333.952 0.109

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zomedica Business Description

Address 1101 Technology Drive, Suite 100, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.